Linden Thomson, senior fund manager at Candriam, notes that weight-loss drugs have become the driver of healthcare investing. “The obesity opportunity is one that people can really understand and has ...

Fiscal math, the leverage enjoyed by fiscal hawks, and a second chance for repealing Obamacare could all mean big-time cuts ...

In an effort to win back customers, Starbucks announced “coffeehouse amenities,” including free refills — with a catch — and ...

Kennedy Jr., is before the Senate Finance Committee at 10 a.m., and you can expect wall-to-wall coverage on TV networks. You ...

People tend to like their Medicare Advantage plans — until they don’t. Consider the case of Rose LaChapelle, who says the Medicare Advantage plan that was supposed to provide care for her 92 ...

President Trump reportedly held a “fiery” call with Denmark’s Prime Minister Mette Frederiksen over the president’s insistence that U.S. control of Greenland is necessary for American ...

Trump has also questioned whether Denmark, which has controlled Greenland since 1814, has a "legal right" to the territory and predicted that Greenland's people will vote to join the U.S. He ...

Donald Trump has made clear to Mette Frederiksen, Denmark’s prime minister, that he wants to place Greenland under American control. But Mr Høyem said that Mr Trump would require approval from ...

Jefferies analyst Peter Welford maintained a Sell rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK515.00.

Goldman Sachs analyst James Quigley maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK875.00.

It has been a good week for CSL Behring as it rolls out haemophilia B gene therapy Hemgenix, with positive reimbursement decisions in both the UK and Denmark. In the UK, health technology ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat substance abuse disorders, psychosis, infections, cancer and dementia, a sweeping ...